ReviewFrontiers in pharmacology2025
Curcumin mediates oxidative stress to play an anti-fibrotic role, focusing on liver, renal, myocardial and pulmonary fibrosis.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- TMetabolic brain disease · 2026Article
- Antifibrotic mechanism of curcumin and its therapeutic potential in multi-organ diseases.Frontiers in pharmacology · 2026Review
- Exploring the roles of genes associated with leukocyte transendothelial migration in liver cirrhosis development.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Curcumin is a natural polyphenolic compound that originates from turmeric ( Objective: This comprehensive review aims to delineate the recent progress in comprehending the role of curcumin in modulating oxidative stress and exerting an anti-fibrotic effect, with a particular focus on liver, renal, myocardial, and pulmonary fibrosis. Methods: A systematic review of the literature was conducted via the PubMed, Web of Science, Google Scholar, and China National Knowledge Infrastructure, covering 2000 until 2024. A systematic review identified studies examining curcumin's regulation of oxidative stress pathways in therapeutic strategies for multiple fibrotic disorders, which were analyzed to synthesize current evidence. Results: In recent years, the application of curcumin for the clinical management of fibrotic diseases in a variety of clinical applications has been extensively investigated. Accumulating evidence suggests that curcumin can exert antifibrotic effects by ameliorating oxidative stress through the modulation of various signaling pathways such as regulating reactive oxygen species (ROS), nuclear factor erythroid-2-related factor 2 (NRF2), peroxisome proliferator-activated receptors (PPAR), transforming growth factor- β1 (TGF-β1). In this review, we investigate the pharmacokinetics of curcumin, the relationship between oxidative stress and the pathogenesis of fibrosis, and summarize the related studies of curcumin in the treatment of fibrotic diseases by regulating oxidative stress. Conclusion: This comprehensive review elucidates curcumin's antifibrotic potential and explores its translational applications in developing novel therapeutic strategies to combat fibrotic pathologies, supported by mechanistic evidence that informs safer, more effective treatment paradigms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.